Drugs / B10 L-BPA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07003139 | Jun 2025 → Jun 2026 overdue | brain cancer | China Medical University Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06668987 | Oct 2024 → Aug 2025 | meningioma | Heron Neutron Medical Corp. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06952868 | May 2025 → Aug 2026 overdue | head and neck cancer | China Medical University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B10 L-BPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06952868 ↗ |
| Known as | B10 L-BPA Injection | “The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.” NCT06952868 ↗1“The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.” NCT07003139 ↗ |